SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (13396)10/7/2004 1:22:31 PM
From: Michael Young  Read Replies (1) of 52153
 
<<but imo, that's what couragious and principled medical behavior is about... Topol will now profit from the consulations, expert witness requests, interviews, lectures,etc, etc...imo, there was much self-interest and less public health interest in his editorial today..>>

There is no doubt that Topol is well positioned to get paid in a big way through litigation work. But the bottom line is that he was in a group raising concerns about the drug several years ago. You can claim he should have thrown himself in front of the Merck marketing train, but that is easier said than done.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News